Last Price
3.44
Today's Change
-0.05 (1.43%)
Day's Change
3.34 - 3.55
Trading Volume
1,441,773
Market Cap
214 Million
Shares Outstanding
62 Million
Avg Volume
1,694,466
Avg Price (50 Days)
8.25
Avg Price (200 Days)
7.90
PE Ratio
-10.12
EPS
-0.34
Earnings Announcement
05-Nov-2024
Previous Close
3.49
Open
3.45
Day's Range
3.34 - 3.55
Year Range
2.865 - 13.7
Trading Volume
1,441,773
1 Day Change
-1.43%
5 Day Change
0.00%
1 Month Change
-63.17%
3 Month Change
-46.08%
6 Month Change
-65.94%
Ytd Change
-52.29%
1 Year Change
-20.19%
3 Year Change
-88.89%
5 Year Change
-59.77%
10 Year Change
-74.52%
Max Change
-74.52%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.